These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 27832321)

  • 1. A mathematical analysis of rebound in a target-mediated drug disposition model: II. With feedback.
    Aston PJ; Derks G; Agoram BM; van der Graaf PH
    J Math Biol; 2017 Jul; 75(1):33-84. PubMed ID: 27832321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A mathematical analysis of rebound in a target-mediated drug disposition model: I.without feedback.
    Aston PJ; Derks G; Agoram BM; van der Graaf PH
    J Math Biol; 2014 May; 68(6):1453-78. PubMed ID: 23591581
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transitioning patients from efalizumab to alternative psoriasis therapies: findings from an open-label, multicenter, Phase IIIb study.
    Menter A; Hamilton TK; Toth DP; Leung HM; Wetherill G; Hennessey B; Garovoy M; Kwon P; Pariser DM;
    Int J Dermatol; 2007 Jun; 46(6):637-48. PubMed ID: 17550570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rebound of psoriasis after efalizumab discontinuation, despite being on high-dose cyclosporine.
    Maskatia ZK; Koo J
    J Drugs Dermatol; 2007 Sep; 6(9):941-4. PubMed ID: 17941368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relapse, rebound, and psoriasis adverse events: an advisory group report.
    Carey W; Glazer S; Gottlieb AB; Lebwohl M; Leonardi C; Menter A; Papp K; Rundle AC; Toth D
    J Am Acad Dermatol; 2006 Apr; 54(4 Suppl 1):S171-81. PubMed ID: 16488339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rebound of psoriasis during treatment with efalizumab.
    Golda N; Benham SM; Koo J
    J Drugs Dermatol; 2006 Jan; 5(1):63-5. PubMed ID: 16468294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biologic therapy for psoriasis: the T-cell-targeted therapies efalizumab and alefacept.
    Weinberg JM; Tutrone WD
    Cutis; 2003 Jan; 71(1):41-5. PubMed ID: 12553629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biological therapies (immunomodulatory drugs), worsening of psoriasis and rebound effect: new evidence of similitude.
    Teixeira MZ
    Homeopathy; 2016 Nov; 105(4):344-355. PubMed ID: 27914574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple side effects of Efalizumab in a Saudi female with chronic persistent psoriasis followed by severe rebound after Efalizumab discontinuation.
    Bukhari IA
    Saudi Med J; 2007 Nov; 28(11):1745-7. PubMed ID: 17965804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efalizumab discontinuation: a practical strategy.
    Pugashetti R; Koo J
    J Dermatolog Treat; 2009; 20(3):132-6. PubMed ID: 19459081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An overview of the pharmacokinetics and pharmacodynamics of efalizumab: a monoclonal antibody approved for use in psoriasis.
    Joshi A; Bauer R; Kuebler P; White M; Leddy C; Compton P; Garovoy M; Kwon P; Walicke P; Dedrick R
    J Clin Pharmacol; 2006 Jan; 46(1):10-20. PubMed ID: 16397279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efalizumab in the treatment of psoriasis.
    Leonardi CL
    Dermatol Ther; 2004; 17(5):393-400. PubMed ID: 15379774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infliximab- and methotrexate-resistant rebound of psoriasis after discontinuation of efalizumab (Raptiva).
    Thielen AM; Barde C; Saurat JH
    Br J Dermatol; 2006 Oct; 155(4):846-7. PubMed ID: 16965444
    [No Abstract]   [Full Text] [Related]  

  • 14. Sequential treatment with biologics: switching from efalizumab to etanercept in 35 patients with high-need psoriasis.
    Antoniou C; Dessinioti C; Vergou T; Stratigos AJ; Avgerinou G; Kostaki M; Katsambas A
    J Eur Acad Dermatol Venereol; 2010 Dec; 24(12):1413-20. PubMed ID: 20384690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efalizumab in the treatment of psoriasis: mode of action, clinical indications, efficacy, and safety.
    Schön MP
    Clin Dermatol; 2008; 26(5):509-14. PubMed ID: 18755369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efalizumab.
    Wellington K; Perry CM
    Am J Clin Dermatol; 2005; 6(2):113-8; discussion 119-20. PubMed ID: 15799683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of the Pharmacokinetics, Pharmacodynamics, and Efficacy of a Monoclonal Antibody, Using a Physiologically Based Pharmacokinetic FcRn Model.
    Chetty M; Li L; Rose R; Machavaram K; Jamei M; Rostami-Hodjegan A; Gardner I
    Front Immunol; 2014; 5():670. PubMed ID: 25601866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efalizumab treatment of psoriasis vulgaris: a cohort study in outpatient clinical practice.
    Puig L; Roé E; García-Navarro X; Corella F; Alomar A
    Clin Exp Dermatol; 2009 Jun; 34(4):469-75. PubMed ID: 19077105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical characteristics and disease course in patients treated with efalizumab following suspension of marketing authorization by the European medicines agency: a multicenter observational study].
    Morell L; Carrascosa JM; Ferrándiz C; García-Bustinduy M; Fonseca E; Carretero G; Daudén E; Marrón SE; López-Estebaranz JL; Ferrán M; Sánchez-Regaña M; Muñoz-Santos C; Belinchón I; Puig L;
    Actas Dermosifiliogr; 2011 Jun; 102(5):354-64. PubMed ID: 21530928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efalizumab: new drug. Plaque psoriasis: too many unknowns.
    Prescrire Int; 2006 Feb; 15(81):8-11. PubMed ID: 16548097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.